FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 236 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Καρκίνος Δέρματος January 20, 2019 Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive... February 24, 2023 No Link Between Caffeine Consumption and Breast Cancer, Study Finds September 29, 2021 Load more HOT NEWS Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... 5 Tips for Managing Financial Stress During Cancer Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer Five Questions with…Jennifer.
